[1]
|
刘文东. 原发性肝癌诊疗进展[J]. 中西医结合心血管病电子杂志, 2018, 6(31): 162-163.
|
[2]
|
黄成, 孙惠川. 《原发性肝癌诊疗规范(2019年版)》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(1): 6-9.
|
[3]
|
Han, K. and Kim, J.H. (2015) Transarterial Chemoembolization in Hepatocellular Carcinoma Treatment: Barcelona Clinic Liver Cancer Staging System. World Journal of Gastroenterology, 21, 10327-10335.
https://doi.org/10.3748/wjg.v21.i36.10327
|
[4]
|
Chang, L., Wang, Y., Zhang, J., et al. (2017) The Best Strategy for HCC Patients at Each BCLC Stage: A Network Meta-Analysis of Observational Studies. Oncotarget, 8, 20418-20427. https://doi.org/10.18632/oncotarget.14668
|
[5]
|
闫东. 2018《CSCO原发性肝癌诊疗指南》解读——肝动脉介入治疗部分[J]. 肝癌电子杂志, 2018, 5(3): 4-7.
|
[6]
|
Ogasawara, S., Ooka, Y., Koroki, K., et al. (2020) Switching to Systemic Therapy after Locoregional Treatment Failure: Definition and Best Timing. Clinical and Molecular Hepatology, 26, 155-162.
https://doi.org/10.3350/cmh.2019.0021n
|
[7]
|
Li, L., Zhao, W., Wang, M., et al. (2018) Transarterial Chemoembo-lization plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. BMC Gastroenterology, 18, 138.
https://doi.org/10.1186/s12876-018-0849-0
|
[8]
|
Raoul, J.L., Forner, A., Bolondi, L., Cheung, T.T., Kloeckner, R. and de Baere, T. (2019) Updated Use of TACE for Hepatocellular Carcinoma Treatment: How and When to Use It Based on Clinical Evidence. Cancer Treatment Reviews, 72, 28-36. https://doi.org/10.1016/j.ctrv.2018.11.002
|
[9]
|
Lencioni, R., Petruzzi, P. and Crocetti, L. (2013) Chemoemboliza-tion of Hepatocellular Carcinoma. Seminars in Interventional Radiology, 30, 3-11. https://doi.org/10.1055/s-0033-1333648
|
[10]
|
王瑞航, 姚升娟, 张晨, 等. 肝动脉化疗栓塞介入术对原发性肝癌患者近期疗效及Child-Pugh分级的影响[J]. 医学信息, 2020, 33(17): 101-102.
|
[11]
|
Zhao, M., Xiang, P. and Jiang, H. (2018) TransArterial ChemoEmbolization (TACE) with Platinum versus Anthracyclines for Hepatocellular Carcinoma: A Meta-Analysis. International Journal of Surgery, 53, 151-158.
https://doi.org/10.1016/j.ijsu.2018.03.049
|
[12]
|
Abdelgalil, A.A., Alkahtani, H.M. and Al-Jenoobi, F.I. (2019) So-rafenib. In: Profiles of Drug Substances, Excipients, and Related Methodology, Vol. 44, Elsevier, Amsterdam, 239-266. https://doi.org/10.1016/bs.podrm.2018.11.003
|
[13]
|
Leal, C.R.G., Magalhães, C., Barbosa, D., et al. (2018) Surviv-al and Tolerance to Sorafenib in Child-Pugh B Patients with Hepatocellular Carcinoma: A Prospective Study. Investiga-tional New Drugs, 36, 911-918.
https://doi.org/10.1007/s10637-018-0621-x
|
[14]
|
Ziogas, D.C., Papadatos-Pastos, D., Thillai, K., et al. (2017) Effi-cacy and Safety of Sorafenib in Patients with Advanced Hepatocellular Carcinoma: Age Is Not a Problem. European Journal of Gastroenterology & Hepatology, 29, 48-55. https://doi.org/10.1097/MEG.0000000000000739
|
[15]
|
Zhuang, B.W., Li, W., Xie, X.H., et al. (2019) Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Systematic Review and Me-ta-Analysis. Japanese Journal of Clinical Oncology, 49, 845-855. https://doi.org/10.1093/jjco/hyz069
|
[16]
|
Zhang, X., Wang, K., Wang, M., et al. (2017) Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Oncotarget, 8, 29416-29427. https://doi.org/10.18632/oncotarget.15075
|
[17]
|
Yuan, J., Yin, X., Tang, B., et al. (2019) Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International, 2019, Article ID: 2141859. https://doi.org/10.1155/2019/2141859
|
[18]
|
Huang, Y., Chen, B., Liu, N., et al. (2017) Overall Survival in Response to Sorafenib with Transarterial Chemoembolization for BCLC Stage B Hepatocellular Car-cinoma: Propensity Score Analysis. International Journal of Clinical Pharmacology and Therapeutics, 55, 498-508. https://doi.org/10.5414/CP202787
|
[19]
|
Kok, V.C., Chen, Y.C., Chen, Y.Y., et al. (2019) Sorafenib with Transarte-rial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Na-tionwide Population-Based Cohort Study. Cancers (Basel), 11, 985. https://doi.org/10.3390/cancers11070985
|
[20]
|
Feng, F., Jiang, Q., Jia, H., et al. (2018) Which Is the Best Combi-nation of TACE and Sorafenib for Advanced Hepatocellular Carcinoma Treatment? A Systematic Review and Network Meta-Analysis. Pharmacological Research, 135, 89-101. https://doi.org/10.1016/j.phrs.2018.06.021
|